These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 34519533)

  • 21. Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens.
    Prasad M; Ranjan K; Brar B; Shah I; Lalmbe U; Manimegalai J; Vashisht B; Gaury M; Kumar P; Khurana SK; Prasad G; Rawat J; Yadav V; Kumar S; Rao R
    Curr Drug Metab; 2017; 18(10):942-970. PubMed ID: 28952435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.
    Stukalov A; Girault V; Grass V; Karayel O; Bergant V; Urban C; Haas DA; Huang Y; Oubraham L; Wang A; Hamad MS; Piras A; Hansen FM; Tanzer MC; Paron I; Zinzula L; Engleitner T; Reinecke M; Lavacca TM; Ehmann R; Wölfel R; Jores J; Kuster B; Protzer U; Rad R; Ziebuhr J; Thiel V; Scaturro P; Mann M; Pichlmair A
    Nature; 2021 Jun; 594(7862):246-252. PubMed ID: 33845483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Network-Guided Discovery of Influenza Virus Replication Host Factors.
    Ackerman EE; Kawakami E; Katoh M; Watanabe T; Watanabe S; Tomita Y; Lopes TJ; Matsuoka Y; Kitano H; Shoemaker JE; Kawaoka Y
    mBio; 2018 Dec; 9(6):. PubMed ID: 30563907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Modulation of transcriptomic signature of the infected host: a new therapeutic strategy for the management of severe viral infections? Example of the flu].
    Poissy J; Terrier O; Lina B; Textoris J; Rosa-Calatrava M
    Reanimation; 2016; 25(Suppl 2):53-61. PubMed ID: 32288744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human Macrophages.
    Söderholm S; Kainov DE; Öhman T; Denisova OV; Schepens B; Kulesskiy E; Imanishi SY; Corthals G; Hintsanen P; Aittokallio T; Saelens X; Matikainen S; Nyman TA
    Mol Cell Proteomics; 2016 Oct; 15(10):3203-3219. PubMed ID: 27486199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Host Proteins Identified in Extracellular Viral Particles as Targets for Broad-Spectrum Antiviral Inhibitors.
    Gale TV; Horton TM; Hoffmann AR; Branco LM; Garry RF
    J Proteome Res; 2019 Jan; 18(1):7-17. PubMed ID: 30351952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the potential of adjunct therapy in tuberculosis.
    Rayasam GV; Balganesh TS
    Trends Pharmacol Sci; 2015 Aug; 36(8):506-13. PubMed ID: 26073420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular host factors for SARS-CoV-2 infection.
    Baggen J; Vanstreels E; Jansen S; Daelemans D
    Nat Microbiol; 2021 Oct; 6(10):1219-1232. PubMed ID: 34471255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burgeoning therapeutic strategies to curb the contemporary surging viral infections.
    Akram F; Waheed HM; Shah FI; Haq IU; Nasir N; Akhtar MT; Farooq Gohar U
    Microb Pathog; 2023 Jun; 179():106088. PubMed ID: 37004965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systems Virology and Human Cytomegalovirus: Using High Throughput Approaches to Identify Novel Host-Virus Interactions During Lytic Infection.
    Lee CH; Grey F
    Front Cell Infect Microbiol; 2020; 10():280. PubMed ID: 32587832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomics of
    Hoffmann E; Machelart A; Song OR; Brodin P
    Front Immunol; 2018; 9():86. PubMed ID: 29441067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases.
    Mohammadi Pour P; Fakhri S; Asgary S; Farzaei MH; Echeverría J
    Front Pharmacol; 2019; 10():1207. PubMed ID: 31787892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases.
    Li Z; Wu J; Zhou J; Yuan B; Chen J; Wu W; Mo L; Qu Z; Zhou F; Dong Y; Huang K; Liu Z; Wang T; Symmes D; Gu J; Sho E; Zhang J; Chen R; Xu Y
    mBio; 2021 Oct; 12(5):e0254221. PubMed ID: 34634931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein S-Nitrosylation of Human Cytomegalovirus pp71 Inhibits Its Ability To Limit STING Antiviral Responses.
    Nukui M; Roche KL; Jia J; Fox PL; Murphy EA
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32581105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV Exploits Antiviral Host Innate GCN2-ATF4 Signaling for Establishing Viral Replication Early in Infection.
    Jiang G; Santos Rocha C; Hirao LA; Mendes EA; Tang Y; Thompson GR; Wong JK; Dandekar S
    mBio; 2017 May; 8(3):. PubMed ID: 28465428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control.
    Yang KC; Lin JC; Tsai HH; Hsu CY; Shih V; Hu CJ
    Drug Deliv Transl Res; 2021 Aug; 11(4):1420-1437. PubMed ID: 33748879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactome analysis of the influenza A virus transcription/replication machinery identifies protein phosphatase 6 as a cellular factor required for efficient virus replication.
    York A; Hutchinson EC; Fodor E
    J Virol; 2014 Nov; 88(22):13284-99. PubMed ID: 25187537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.